Edwards Lifesciences Q4 Sales Up 13.3% While EPS Misses, Sets 2026 Targets
Edwards Lifesciences posted 13.3% year-over-year Q4 sales growth driven by strong TAVR demand, while adjusted EPS missed estimates and gross margin declined 0.8%. It reaffirmed 2026 sales growth of 8%–10% and EPS of $2.90–3.05, sending shares up about 4% and backed by two-thirds of analysts with roughly 25% upside potential.
1. Q4 2025 Earnings and Performance
Edwards Lifesciences reported Q4 sales growth of 13.3% driven by robust transcatheter aortic valve replacement demand and the latest SAPIEN valve iteration, though adjusted EPS fell short of analyst expectations and gross profit margin decreased by 0.8% year-over-year.
2. 2026 Outlook and Market Response
The company reiterated full-year 2026 targets of 8%–10% sales growth and EPS between $2.90 and $3.05, resulting in a roughly 4% share price increase in after-hours trading and supported by two-thirds of analysts holding Buy ratings with about 25% upside potential.